CoChat

Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial

Open access
Carrato, Alfredo, Swieboda-Sadlej, Anna, Staszewska-Skurczynska, Marzanna, Lim, Robert, Roman, Laslo, Shparyk, Yaroslav, Bondarenko, Igor, Jonker, Derek J., Sun, Yan, De la Cruz, Jhony A., Williams, J. Andrew, Korytowsky, Beata, Christensen, James G., Lin, Xun, Tursi, Jennifer M., Lechuga, Maria J., Van Cutsem, Eric · 2013 · Journal of Clinical Oncology
Cited by 136

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Purpose: This double-blind, phase III study aimed to demonstrate that sunitinib plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus FOLFIRI in previously untreated metastatic colorectal cancer (mCRC). Patients and Methods: Patients were randomly assigned to receive FOLFIRI and either sunitinib (37.5 mg per day) or placebo (4 weeks on treatment, followed by 2 weeks off [schedule 4/2]) until disease progression. The primary end point was progression-free survival (PFS). Secondary end points included overall survival, safety, and patient-reported outcomes. The correlation between genotype and clinical outcomes was also analyzed. Results: In all, 768 patients were randomly assigned to sunitinib plus FOLFIRI (n = 386) or placebo plus FOLFIRI (n = 382). Following a second prespecified interim analysis, the study was stopped because of potential futility of sunitinib plus FOLFIRI. Final results are reported. The PFS hazard ratio was 1.095 (95% CI, 0.892 to 1.344; one-sided stratified log-rank P = .807), indicating a lack of superiority for sunitinib plus FOLFIRI. Median PFS for the sunitinib arm was 7.8 months (95% CI, 7.1 to 8.4 months) versus 8.4 months (95% CI, 7.6 to 9.2 months) for the placebo arm. Sunitinib plus FOLFIRI was associated with more grade ≥ 3 adverse events and laboratory abnormalities than placebo (especially diarrhea, stomatitis/oral syndromes, fatigue, hand-foot syndrome, neutropenia, thrombocytopenia, anemia, and febrile neutropenia). More deaths as a result of toxicity (12 v four) and significantly more dose delays, dose reductions, and treatment discontinuations occurred in the sunitinib arm. Conclusion: Sunitinib 37.5 mg per day (schedule 4/2) plus FOLFIRI is not superior to FOLFIRI alone and has a poorer safety profile. This combination regimen is not recommended for previously untreated mCRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2012.45.1930

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 136

Metadata

Authors
Carrato, A., Swieboda-Sadlej, A., Staszewska-Skurczynska, M., Lim, R., Roman, L., Shparyk, Y., Bondarenko, I., Jonker, D. J., Sun, Y., De la Cruz, J. A., Williams, J. A., Korytowsky, B., Christensen, J. G., Lin, X., Tursi, J. M., Lechuga, M. J., & Van Cutsem, E.
Venue
Journal of Clinical Oncology
Published
2013-04-01
Volume
31
Issue
10
Pages
1341-1347
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2116556031
Cited by
136
References
4
FWCI
11.22
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial. https://app.cochat.ai/papers/10.1200/jco.2012.45.1930
The paper
Carrato, A., Swieboda-Sadlej, A., Staszewska-Skurczynska, M., Lim, R., Roman, L., Shparyk, Y., Bondarenko, I., Jonker, D. J., Sun, Y., De la Cruz, J. A., Williams, J. A., Korytowsky, B., Christensen, J. G., Lin, X., Tursi, J. M., Lechuga, M. J., & Van Cutsem, E. (2013). Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.45.1930

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.